Patents by Inventor Callum SLOSS

Callum SLOSS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR INCREASING EFFICACY OF IMMUNOCONJUGATES TARGETING ADAM9 FOR THE TREATMENT OF CANCER
    Publication number: 20240165256
    Abstract: The present disclosure provides methods of treating cancer in a subject who has an increased level of ADAM9 expression. The method comprises administering to the subject a therapeutically effective amount of an anti-ADAM9 immunoconjugate. Also provided is a method of increasing the efficacy of cancer treatment with an anti-ADAM9 immunoconjugate in a subject who has an increased level of ADAM9 expression.
    Type: Application
    Filed: March 7, 2022
    Publication date: May 23, 2024
    Inventors: Eric Henry Westin, Callum Sloss, Krystal Marie Watkins, Deryk T. Loo, Juniper A. Scribner, Francine Zhifen Chen
  • METHODS OF TREATMENT USING ANTI-CD123 IMMUNOCONJUGATES
    Publication number: 20230312735
    Abstract: Methods of administering immunoconjugates that bind to CD123 are provided. The methods comprise administering an anti-CD123 immunoconjugate (e.g., IMGN632) to a subject in need thereof, for example, a patient with a hematologic malignancy, at a therapeutically effective dose regimen that results in treatment of the hematologic malignancy.
    Type: Application
    Filed: November 9, 2022
    Publication date: October 5, 2023
    Inventors: Patrick ZWEIDLER-MCKAY, Kerry CULM-MERDEK, Callum SLOSS, Angela ROMANELLI
  • TREATMENT OF CANCER IN PATIENTS WITH SOLUBLE FR-ALPHA
    Publication number: 20230112620
    Abstract: The present disclosure demonstrates that the amount of soluble folate receptor alpha (FR?) present in a cancer patient is a strong predictor of the efficacy of FR?-targeting therapies. Surprisingly, increased levels of soluble FR? are associated with improved outcomes. Accordingly, the present disclosure provides methods for treating cancer in patients with soluble FR? and methods for identifying a cancer as likely to respond to an anti-FR? therapy based on soluble FR? levels.
    Type: Application
    Filed: June 2, 2022
    Publication date: April 13, 2023
    Applicant: ImmunoGen, Inc.
    Inventors: Eric WESTIN, Jiuzhou WANG, Callum SLOSS
  • Methods for improving anti-CD37 immunoconjugate therapy
    Patent number: 11278629
    Abstract: Methods for identifying and treating patients having cancer who are likely to respond to treatment with an anti-CD37 immunoconjugate (e.g., IMGN529) are provided.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: March 22, 2022
    Assignee: DEBIOPHARM INTERNATIONAL, S.A.
    Inventors: Francesco Bertoni, Angela Romanelli, Callum Sloss
  • METHODS OF TREATMENT USING ANTI-CD123 IMMUNOCONJUGATES
    Publication number: 20200157228
    Abstract: Methods of administering immunoconjugates that bind to CD123 are provided. The methods comprise administering an anti-CD123 immunoconjugate (e.g., IMGN632) to a subject in need thereof, for example, a patient with a hematologic malignancy, at a therapeutically effective dose regimen that results in treatment of the hematologic malignancy.
    Type: Application
    Filed: October 30, 2019
    Publication date: May 21, 2020
    Inventors: Patrick ZWEIDLER-MCKAY, Kerry CULM-MERDEK, Callum SLOSS, Angela ROMANELLI
  • METHODS FOR IMPROVING ANTI-CD37 IMMUNOCONJUGATE THERAPY
    Publication number: 20200054763
    Abstract: Methods for identifying and treating patients having cancer who are likely to respond to treatment with an anti-CD37 immunoconjugate (e.g., IMGN529) are provided.
    Type: Application
    Filed: November 2, 2017
    Publication date: February 20, 2020
    Inventors: Francesco BERTONI, Angela ROMANELLI, Callum SLOSS